SBR Network
  • Home
  • About SBR
  • Topics
    • Business & Markets
    • Economy
    • Education
    • Entertainment
    • Finance
    • Food & Drinks
    • Healthcare
    • Home
    • News
    • Sports
    • Technology
  • Contact SBR
  • Pages
    • Team Info
    • Privacy Policy
    • Editorial Policy
    • Cookie Policy
No Result
View All Result
SBR Network
  • Home
  • About SBR
  • Topics
    • Business & Markets
    • Economy
    • Education
    • Entertainment
    • Finance
    • Food & Drinks
    • Healthcare
    • Home
    • News
    • Sports
    • Technology
  • Contact SBR
  • Pages
    • Team Info
    • Privacy Policy
    • Editorial Policy
    • Cookie Policy
No Result
View All Result
SBR Network
No Result
View All Result

Digital health start-up once worth $1.5 billion is racing to keep lights on as investors flee

mm by Richard Bell
1 year ago
in Healthcare
0
Digital health start-up once worth $1.5 billion is racing to keep lights on as investors flee
401
SHARES
2.4k
VIEWS
Share on FacebookShare on Twitter

Proteus Digital Health has spent two decades trying to develop “smart pills” that can be used to tell a smartphone app whether patients have taken their medications. The technology was so promising that, three years ago, investors valued the company at $1.5 billion.

But Proteus has struggled to turn its vision into reality and is now desperate for cash after an expected $100 million funding round recently fell through, according to people familiar with the matter. To preserve enough money to stay afloat, the company furloughed the majority of its employees for about two weeks in November, said the people, who asked not to be named because the information is confidential.

As 2019 wraps up, Proteus has become the latest Silicon Valley company that’s gone from a one-time high flyer, raising a total of over $500 million, to deep in crisis mode after its partnership with a large pharmaceutical company failed to materialize in a way that could justify its valuation. It’s an ominous sign for the digital therapeutics space, which has lured major investors but has struggled to find breakout successes and has seen big drugmakers walk away from key partnerships.

At Proteus, the furloughed employees were brought back to work in recent weeks after the company was able to land $5 million in emergency funding, according to people with knowledge of the matter. But with roughly 300 people on staff, according to LinkedIn, that money may not last long. Executives at three other digital health companies said they’ve seen an uptick in resumes from Proteus employees in the past few weeks.

“Proteus is currently conducting an operational review and restructuring our business to optimize effectiveness,” a company spokesperson told CNBC in an email. “We are taking into consideration the impact of our restructuring on employees, patients, customers, partners and investors.”

The problem Proteus was trying to tackle is real. Patients don’t always take their meds and don’t necessarily know if they’re up to date with them. Researchers estimate that a lack of adherence to prescriptions results in $100 billion to $300 billion in costs tied to health-care spending and loss of productivity.

With that backdrop, Novartis invested in Proteus in 2010, an agreement that allowed the drugmaker to license Proteus technology for organ transplantation, following a small study to track patients’ compliance with their blood pressure drugs. Later, Proteus moved into mental health, developing digestable sensors that send a notice to users’ smartphones, indicating whether they’re properly medicated or if they missed a dosage. The system also includes wearable patches that detect responses to medicines, as well as mobile apps and data analytics software for hospitals to track intervention.

In 2017, Proteus announced a partnership with pharmaceutical company Otsuka for a digital medicine system called Abilify Mycite and received approval from the Food and Drug Administration. As part of the deal, Otsuka agreed to invest $88 million, including some equity and other funds for development. The landmark regulatory clearance allowed the companies to combine a pill and a patch, which had been previously and separately approved by regulators, into a therapy for people with schizophrenia, bipolar disorder and depression.

But the treatment never gained material traction with patients, according to two people familiar with the matter, making it hard to keep top talent. The company has experienced a wave of high-level departures in the past few years, such as Chief Commercial Officer Molly O’Neill, who left in 2018.

Raising additional money also became a bigger challenge. Otsuka wasn’t willing to put in more cash and other potential investors were waiting for data from the Otsuka deal before writing a check, the people said, even if they were intrigued by the first-of-its-kind digital medicine system.

“The problem is that pharma hasn’t rationalized a way to incorporate digital or sell digital-only interventions,” said Bill Evans, CEO of digital health venture fund Rock Health, who was speaking about the industry generally. “When it comes to pharma and digital, it’s been a challenge to match the cultures and really start to execute.”

A spokesperson for Otsuka’s U.S. unit said in an emailed statement that the company has had a “strong collaboration for many years” with Proteus, “from clinical development to FDA approval to commercial availability.” The representative didn’t comment on current plans, saying only that “Otsuka is committed to its digital medicine program and we are excited about the future and our role in providing an innovative approach to systematically assist patients and their family caregivers by helping to inform the patient’s illness management and personalized treatment plan.”

Proteus isn’t alone. Pear Therapeutics, a digital therapeutics company working on apps for substance use disorders, just lost a key partnership with Sandoz, the generics division of Novartis.

Their experiences underscore the limitations of advanced digital therapies. Pharmaceutical companies don’t have a roadmap yet to get the products out widely to patients or clinicians, regulatory agencies have been slow to approve them and insurers haven’t established clear reimbursement plans. It’s also not obvious who should be monitoring patients if they stop taking medications.

Proteus is “a really interesting technology, but it is a lot to ask of a patient to play along with this kind of system, which involves a pill and patch,” said Christine Lemke, a co-founder of Evidation Health, a digital health company that works with pharmaceutical companies.

Proteus has started focusing on other conditions outside of mental health. In 2017, it moved into oncology and infectious disease with a digital cancer chemotherapy pill. The company has also touted its Discover product, targeted at people with chronic conditions, as its equivalent of Tesla’s Model X. In its statement to CNBC, the company described Discover as a “valuable near-term opportunity.”

While the company has gained accolades for its early efforts to improve health care in innovative ways, that doesn’t always translate into a successful business.

“These companies are plowing the field for the industry,” said Steve Kraus, a health investor at Bessemer Venture Partners. “I can’t stress enough how hard that is.”

Previous Post

Minecraft Bedrock Version Coming to PS4

Next Post

Away replaces CEO Steph Korey after Verge investigation

mm

Richard Bell

When it comes to stories in the healthcare sector which are making ripples, and waves in the global market scenario, Global Market Release relies most on Richard Bell. His eye for detail, and skills when it comes to spotting stories which matter makes him invaluable to the team. His commitment to the healthcare sector proves him to be the best man for the job.

Next Post
Away replaces CEO Steph Korey after Verge investigation

Away replaces CEO Steph Korey after Verge investigation

  • All
  • Education
How to Gamble on Sports: The Ultimate Guide
Sports

How to Gamble on Sports: The Ultimate Guide

by Nicole Haley
January 15, 2021
0

According to a survey conducted last summer, about 33 million American adults said that they planned on betting on NFL...

Read more
Daniel Snyder the Team Owner and Dan Snyder the Community Leader

Daniel Snyder the Team Owner and Dan Snyder the Community Leader

January 14, 2021
Covid Safety: Foams, Sprays, Wipes- What is Better

Covid Safety: Foams, Sprays, Wipes- What is Better

December 29, 2020
What You Need to Understand About the SBI PO Question Paper

What You Need to Understand About the SBI PO Question Paper

December 29, 2020
What Is Mediclaim? Mediclaim Policy Vs Health Insurance

What Is Mediclaim? Mediclaim Policy Vs Health Insurance

December 22, 2020

Recent Posts

  • How to Gamble on Sports: The Ultimate Guide January 15, 2021
  • Daniel Snyder the Team Owner and Dan Snyder the Community Leader January 14, 2021
  • Covid Safety: Foams, Sprays, Wipes- What is Better December 29, 2020
  • What You Need to Understand About the SBI PO Question Paper December 29, 2020
  • What Is Mediclaim? Mediclaim Policy Vs Health Insurance December 23, 2020
  • Why choose fingerprint Jewelry? December 16, 2020
  • How to Get Instagram Likes with a Unique Content December 12, 2020
  • Tips to get Positive Vibes in Your Apartments December 2, 2020

Archives

  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
January 2021
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Dec    
Healthcare

Covid Safety: Foams, Sprays, Wipes- What is Better

In the purview of the looming risk of the COVID-19 risk, there are certain safety and hygiene norms that you ...

December 29, 2020
Healthcare

If You’re Going to Wear a Mask, Here’s What You Should Know

Face masks are showing up more often as some states are seeing an up-tick in coronavirus cases. In states where ...

July 21, 2020
Healthcare

How to Effectively Deal with Difficult Emotions?

Emotions like sadness, pessimism, loneliness, anger, fear, depression, self-criticism, jealousy, rejection, etc. are difficult to ignore at times. But, negative ...

June 19, 2020
Healthcare

How To Get Ideal Hair Transplant Surgery In Delhi?

Hair transplant industry is growing rapidly in the present era as the demand of the procedure is very high. Hair ...

May 23, 2020
Healthcare

Visiting An ER: Don’t Downplay Potentially Serious Symptoms

The emergency room is treated by many people as a one-stop-shop for healthcare. This causes unnecessary strain on our medical ...

April 30, 2020

Categories

  • Business & Markets
  • Economy
  • Education
  • Entertainment
  • Finance
  • Food & Drinks
  • Healthcare
  • Home
  • Life
  • News
  • Sports
  • Technology

Recent News

How to Gamble on Sports: The Ultimate Guide

How to Gamble on Sports: The Ultimate Guide

January 15, 2021
Daniel Snyder the Team Owner and Dan Snyder the Community Leader

Daniel Snyder the Team Owner and Dan Snyder the Community Leader

January 14, 2021
  • About
  • Our Team
  • Advertise
  • Privacy Policy
  • Get In Touch

Copyright @ 2020 SBR Network.

No Result
View All Result
  • About SBR Network News
  • Contacting SBR Network
  • Cookie Policy
  • Editorial Policy
  • Get In Touch
  • Home
  • Home 1
  • Privacy Policy
  • Team Info

Copyright @ 2020 SBR Network.